Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 204

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity

Open access
Solomon, Isabelle, Amann, Maria, Goubier, Anne, Arce Vargas, Frederick, Zervas, Dimitrios, Qing, Chen, Henry, Jake Y., Ghorani, Ehsan, Akarca, Ayse U., Marafioti, Teresa, Śledzińska, Anna, Werner Sunderland, Mariana, Franz Demane, Dafne, Clancy, Joanne Ruth, Georgiou, Andrew, Salimu, Josephine, Merchiers, Pascal, Brown, Mark Adrian, Flury, Reto, Eckmann, Jan, Murgia, Claudio, Sam, Johannes, Jacobsen, Bjoern, Marrer-Berger, Estelle, Boetsch, Christophe, Belli, Sara, Leibrock, Lea, Benz, Joerg, Koll, Hans, Sutmuller, Roger, Peggs, Karl S., Quezada, Sergio A. · 2020 · Nature Cancer

Abstract

Intratumoral regulatory T (Treg) cell abundance associates with diminished antitumor immunity and poor prognosis in human cancers. Recent work demonstrates that CD25, the high-affinity receptor subunit for interleukin (IL)-2, is a selective target for Treg depletion in mouse and human malignancies; however, anti-human CD25 antibodies have failed to deliver clinical responses against solid tumors due to bystander IL-2 receptor signaling blockade on effector T cells, which limits their antitumor activity. Here we demonstrate potent single-agent activity of anti-CD25 antibodies optimized to deplete Treg cells, while preserving IL-2-STAT5 signaling on effector T cells and show synergy with immune checkpoint blockade in vivo. Pre-clinical evaluation of an anti-human CD25 (RG6292) antibody with equivalent features demonstrates, in both nonhuman primates and humanized mouse models, efficient Treg cell depletion with no overt immune-related toxicities. Our data support the clinical development of RG6292 and evaluation of new combination therapies incorporating non-IL-2-blocking anti-CD25 antibodies in clinical studies. Quezada and colleagues develop improved anti-CD25 antibodies that preserve IL-2 signaling and enhance single-agent antitumor immunity and immunotherapy through specific and efficient Treg cell depletion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43018-020-00133-0

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 204

Metadata

Authors
Solomon, I., Amann, M., Goubier, A., Arce Vargas, F., Zervas, D., Qing, C., Henry, J. Y., Ghorani, E., Akarca, A. U., Marafioti, T., Śledzińska, A., Werner Sunderland, M., Franz Demane, D., Clancy, J. R., Georgiou, A., Salimu, J., Merchiers, P., Brown, M. A., Flury, R., Eckmann, J., Murgia, C., Sam, J., Jacobsen, B., Marrer-Berger, E., Boetsch, C., Belli, S., Leibrock, L., Benz, J., Koll, H., Sutmuller, R., Peggs, K. S., & Quezada, S. A.
Venue
Nature Cancer
Published
2020-11-09
Volume
1
Issue
12
Pages
1153-1166
ISSN
2662-1347 (ISSN-L)
OpenAlex
W3098454574
Cited by
204
References
13
FWCI
6.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. https://app.cochat.ai/papers/10.1038/s43018-020-00133-0
The paper
Solomon, I., Amann, M., Goubier, A., Arce Vargas, F., Zervas, D., Qing, C., Henry, J. Y., Ghorani, E., Akarca, A. U., Marafioti, T., Śledzińska, A., Werner Sunderland, M., Franz Demane, D., Clancy, J. R., Georgiou, A., Salimu, J., Merchiers, P., Brown, M. A., Flury, R., . . . Quezada, S. A. (2020). CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity. Nature Cancer. https://doi.org/10.1038/s43018-020-00133-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.